Business Wire

Dr. Philippe Chambon Joins Pharnext’s Board of Directors

Jaa

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its board of directors has appointed Dr. Philippe Chambon as a new, independent, non-executive member. He is replacing Jacques Attali for the remainder of the term, until the Annual Shareholder’s meeting is called to approve the 2018 financial statements.

Dr. Chambon, M.D, Ph.D., is a well-known healthcare professional who has spent 22 years as a venture capital investor in the U.S., primarily focused on biopharmaceutical and digital health companies. He led the creation of New Leaf Venture Partners as a spin-off from the Sprout Group. As such, he served on numerous boards of both private and public companies, including Auxilium Pharmaceuticals (acquired by Endo), ePocrates Inc. (acquired by AthenaHealth), Truveris and NxStage Medical (acquisition by Fresenius Medical Care pending).

“We thank Jacques Attali for his unique and precious contribution during the years he served on our board” said Michel de Rosen, Chairman of Pharnext’s Board of Directors. “We are delighted that Philippe is joining us. His experience, expertise, and judgement are invaluable and will help Pharnext reach the next level and deliver the innovative treatments we are working on.”

Dr. Chambon added: “I am honored to have the opportunity to work alongside Daniel, Michel and the whole Pharnext team. The Company’s unique focus on the clear opportunity that drug combinations represent has the potential to be truly revolutionary.”

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com

Contact information

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
VP, Chief Commercial Officer
contact@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Aurore Gangloff
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
RooneyPartners
Marion Janic, +1 212 223 4017
mjanic@rooneyco.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients26.4.2018 12:08Tiedote

In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis. BCD-085 is an original monoclonal antibody drug blocking interleukin-17, a cytokine playing a key role in developing and maintaining various autoimmune and immunoinflammatory diseases. The majority of psoriasis patients have serious psychological problems due to social isolation, while patients with ankylosing spondylitis may rapidly become disabled if diagnosed late or treated inappropriately. Both diseases are a serious medical and social challenge, especially because they often affect young people of working age (22 to 35 years old). The European market of IL-17 inhibitors is over $700 million and it’s going to grow to $1 677 million within next 5 years. BIOCAD expects to occupy an essential share of this perspective ma

Ecole hôtelière de Lausanne (EHL) Wins Best Employer Ranking26.4.2018 11:17Tiedote

Ecole hôtelière de Lausanne (EHL) wins the title of Best Employer in French-speaking Switzerland in the category of medium-sized companies in the annual ranking of the magazine Bilan published this week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426005645/en/ Ecole hôtelière de Lausanne (EHL) Offering a dynamic and pleasant work environment on the campus north of Lausanne, the 464 employees of 33 nationalities benefit, among other things, from home-office opportunities, seven weeks of vacation, access to sport facilities and up to three free meals a day. Reacting to the announcement, CEO of the EHL Group, Mr Rochat said "the quality of the work environment is one of the priorities set for the EHL management. It is important for us to be able to attract and retain the best talent to continue to provide the best training to our students, and maintain our leadership position in teaching Hospitality Management. We work o

Ripple Grows Its Global Payments Network With Five New xVia Customers26.4.2018 11:00Tiedote

Ripple, the enterprise blockchain solution for global payments, is announcing that five new customers across Europe and Asia - FairFX (U.K.), RationalFX (U.K.), Exchange4Free (U.K.), UniPAY (Georgia), and MoneyMatch (Malaysia) - will use xVia to power frictionless payments over RippleNet. Requiring just one standard integration, xVia is an API solution enabling payment originators - those sending a payment on behalf of a customer, but not actually processing and paying it out - to access and reap the benefits of RippleNet. This includes faster entry into new markets, lower operational costs, increased speed and end-to-end visibility over a payment’s journey. “By tapping our global network with xVia, our customers now access new markets quicker and cost efficiently,” said Asheesh Birla, senior vice president of product at Ripple. “All of these customers run into the same problem: building bespoke connections to banks and networks all over the world. It’s expensive and time consuming. xV

Alibaba Cloud Receives MySQL Corporate Contributor Award26.4.2018 11:00Tiedote

Alibaba Cloud, the cloud computing arm of Alibaba Group, has won the 2018 MySQL Community Awards: Corporate Contributor, which recognizes its contribution to the MySQL ecosystem, the world’s most popular open source database. The award, presented earlier this week at the Percona Live conference held in Santa Clara, California, is another accolade for the global cloud services provider. The award recognized Alibaba Cloud’s contributions to the open source communities and its efforts to empower developers around the world in recent years. Today, more than one hundred thousand MySQL instances are running on ApsaraDB for RDS, Alibaba Cloud’s relational database services. This is the second time Alibaba has received the coveted award from the MySQL community. In 2015, Alibaba Group became the first Asian company to be named a WebScaleSQL Contributor, alongside Facebook, Google, Twitter and LinkedIn. The award is a ‘from-the-community, by-the-community, and for-the-community’ initiative and

Bentley Systems Acquires Plaxis, and Complementary SoilVision, to Integrate Geotechnical Engineering within Digital Workflows for Infrastructure Projects26.4.2018 09:00Tiedote

Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced the acquisition of Plaxis, the leading provider of geotechnical software, based in Delft, Netherlands, and the agreement to acquire soil engineering software provider SoilVision, based in Saskatchewan, Canada. The acquisitions, with Bentley’s market-leading borehole reporting and data management software gINT, serve to make Bentley a complete source for geotechnical professionals “going digital.” Finally, BIM advancements can be extended to the essential subsurface engineering of every infrastructure project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425006935/en/ PLAXIS 3D performs three-dimensional analysis of deformation, soil-structure interaction, and stability in geotechnical engineering and rock mechanics. Projects necessarily begin with geotechnical surveys and sampling, c

Waterstones announces Change of Ownership26.4.2018 09:00Tiedote

Waterstones, the leading UK bookseller, announces today that it has entered into a binding agreement to be acquired and financed by funds managed by Elliott Advisors (UK) Ltd (“Elliott”). Waterstones operates a chain of 283 bookshops located across the UK and in Ireland, The Netherlands and Belgium. It had sales of over £400 million in the year to the end of April 2017. Lynwood Investments, controlling shareholder of Waterstones since 2011, will retain a minority stake. Founded in 1977, Elliott is one of the oldest and largest private investment organisations globally, with funds under management of approximately $35 billion. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott has an active and growing presence in private equity, investing globally with notable past and current investments including ASG Technologies, Charter Court Financial Services, Dell Software, Gigamon, Game Digital

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme